Biopharma manufacturers turn to flexible, modular facilities to meet diverse therapy demands

Biopharma development is increasingly focused on specialized and personalized treatments such as cell and gene therapies, antibody-drug conjugates and monoclonal antibodies. At the same time, the market continues to demand large-scale products like GLP-1 drugs, vaccines and biosimilars.

These diverse product needs create regulatory complexity, fragile supply chains and variable patient demand. Sponsors therefore expect their contract manufacturing organizations to be able to adjust quickly, especially when timelines are compressed to reach the market or secure funding.

Manufacturers that rely on fixed suites and dedicated equipment struggle to meet such expectations. CDMOs that build modular facilities, maintain cross-trained staff and adopt a partnership mindset can reconfigure capacity and processes on short notice.

Kyle Kissick, MSAT lead at a leading CDMO, says flexibility means working closely with pharma partners' technical and quality teams to bring processes onto the site efficiently while preserving high quality and the ability to scale.